more_reports

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock.

Canadian Healthcare Co. Showcases Stable FQ424

Research Report
  ()
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data

  ()
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next.

Virtual Healthcare Breakthrough Expanding Access for 6.9M Medicaid Patients in New York

  ()
Rocket Doctor, under Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), is now an in-network provider for New York Medicaid, expanding virtual healthcare access to 6.9 million beneficiaries. Find out how this milestone offers the possibility to reshape healthcare accessibility.

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.

Healthcare Tech Co. To Acquire Digital Health Platform

  ()
This will expand its ecosystem of AI-powered products. Read on to learn more about its offerings and rapidly growing sector.

New Strategic Moves Aim To Accelerate Growth in AI Healthcare

  ()
Light AI Inc. (ALGO:CBOE) announces major marketing campaigns, advisory board appointments, and a key regulatory partnership to drive growth. Discover how these strategic moves could shape the future of AI healthcare.

Kentucky Medical Co. Has Strong Operating Fundamentals

Research Report
  ()
Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note.

AI Stock in an Uptrend That Is Likely To Continue

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Light AI Inc. (ALGO:CBOE) is an Immediate Strong Buy.

Biotech Requests OK to Assess Device in Second Indication

Research Report
  ()
The company behind this possible "pipeline in a device" wants to evaluate it now in thyroid disease after having begun with trials in type 1 diabetes, noted an H.C. Wainwright & Co. report.

Healthcare Pioneer Expands Revolutionary Treatment Platform

  ()
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development."

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company.

Washington D.C. Pharma Co. Receives FDA Acceptance

Research Report
  ()
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst.

Biotech's Target Price 183.757% Higher Than Current

Research Report
  ()
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price.

AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs.

Biopharma Shares Multiple 2025 Catalysts

Research Report
  ()
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co.

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Tech Innovator Achieves Breakthrough Multi-Market Success

  ()
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock.

Advanced AI Solutions Deliver Hope for CNS Cancer Treatment

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation.

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.

Pharma Innovator Reveals Groundbreaking Diabetes Treatment

Research Report
  ()
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share.

Biotech Advances Breakthrough Cancer Treatment Results

Research Report
  ()
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.